Nuvation Bio
Develops cancer medicines led by IBTROZI and a focused oncology pipeline.
$6.65
After-hours close−0.01 (−0.15%)
At close$6.66(−4.72%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 68.22%236.85M sharesInsiders 17.23%59.84M sharesOther 14.55%50.52M shares
Shares outstanding 347.20M · Float 253.59M · 73.0% free float
Institutions13F, as of Jun 30, 2026
251 holders · 236.85M shares · 42 new positions · 153 increased · 52 reduced · 31 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 52.23M | 15.04% | +240.7K | Aug 13, 2026 |
| BlackRock, Inc. | 27.63M | 7.96% | +2.53M | Aug 7, 2026 |
| Decheng Capital LLC | 25.95M | 7.48% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 11.92M | 3.43% | +293.3K | Aug 13, 2026 |
| Omega Fund Management, LLC | 8.08M | 2.33% | 0 | Aug 14, 2026 |
| Laurion Capital Management LP | 7.82M | 2.25% | −2.6K | Aug 13, 2026 |
| State Street Corp | 7.37M | 2.12% | +585.9K | Aug 7, 2026 |
| Geode Capital Management, LLC | 6.24M | 1.80% | +381.2K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 50.60M | 13G | May 12, 2025 ↗ |
| Xiangmin Cuiincl. Decheng Capital Management III (Cayman), LLC, Decheng Capital Global Healthcare GP, LLC +3 more | 8.00% | 26.60M | 13D | Sep 10, 2024 ↗ |
| BlackRock, Inc. | 6.40% | 21.71M | 13G | Jul 17, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| David Hung | director, 10 percent owner, officer: PRESIDENT AND CEO | 59.28M | 17.07% | Jun 18, 2025 |
| Robert Mashal | director | 225.0K | 0.06% | Jun 11, 2026 |
| Colleen Sjogren | officer: Chief Commercial Officer | 81.0K | 0.02% | Jun 18, 2025 |
| Moses Makunje | officer: SEE REMARKS | 68.1K | 0.02% | Mar 3, 2026 |
| Philippe Sauvage | officer: Chief Financial Officer | 54.1K | 0.02% | Jul 17, 2026 |
| Kerry Wentworth | officer: CHIEF REGULATORY OFFICER | 53.0K | 0.02% | Jun 24, 2026 |
| Stacy Markel | officer: CHIEF PEOPLE OFFICER | 32.6K | 0.01% | Jun 24, 2026 |
| David C. Hanley | officer: CHIEF TECHNICAL OPERATIONS | 24.0K | 0.01% | Nov 21, 2025 |
| Dongfang Liu | officer: CHIEF MEDICAL OFFICER | 18.0K | 0.01% | Apr 21, 2026 |
1 ten-percent owner holds 48.17M shares by Form 4, outside the officers-and-directors figure above · 15 people have not refiled in the last 18 months (40.74M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 19, 2026 | Gary Hattersleyofficer: CHIEF SCIENTIFIC OFFICER | Sale | 100,000 | $7.09 | 0 |
| Jun 23, 2026 | Philippe Sauvageofficer: Chief Financial Officer | Sale | 47,668 | $6.01 | 12,673 |
| Jun 23, 2026 | Kerry Wentworthofficer: CHIEF REGULATORY OFFICER | Sale | 63,000 | $6.02 | 53,000 |
| Jun 23, 2026 | Stacy Markelofficer: CHIEF PEOPLE OFFICER | Sale | 125,000 | $6.03 | 32,591 |
| Jun 9, 2026 | Robert Mashaldirector | Purchase | 25,000 | $4.73 | 225,000 |
| Apr 17, 2026 | Dongfang Liuofficer: CHIEF MEDICAL OFFICER | Sale | 50,000 | $5.02 | 18,000 |
| Apr 17, 2026 | Kerry Wentworthofficer: CHIEF REGULATORY OFFICER | Sale | 36,750 | $5.01 | 53,000 |
| Apr 6, 2026 | Kerry Wentworthofficer: CHIEF REGULATORY OFFICER | Sale | 200,000 | $4.52 | 53,000 |
| Dec 1, 2025 | Dongfang Liuofficer: CHIEF MEDICAL OFFICER | Sale | 150,000 | $7.82 | 18,000 |
| Nov 25, 2025 | Dongfang Liuofficer: CHIEF MEDICAL OFFICER | Sale | 10,000 | $7.50 | 18,000 |
CongressHouse and Senate disclosures
Not reported.